CNBC's Meg Tirrell reports Express Scripts is seeking a lower price alternative to Daraprim, a drug that helps prevent infection.» Read More
Pfizer held its shareholder meeting Thursday morning at the historic Memphis hotel where the ducks march through the lobby. I haven't seen the spectacle yet, but I'm told it's quite the scene. Watch my exclusive interview with Chairman and CEO Jeff Kindler.
AstraZeneca nudged up its forecast for 2008 earnings on Thursday, but sales of key products in the first quarter were weaker than hoped for, knocking its shares.
Earnings from a smorgasbord of European companies revealed a mixed business environment Thursday, with the likes of Bayer and Swedbank beating expectations, while Peugeot Citroen and Stora Enso missed.
Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...
German companies dominated European earnings headlines Wednesday with tech heavyweight Infineon reporting a quarterly loss, but IKB, the first German subprime casualty indicating a smaller-than-expected loss.
Schering-Plough, whose shares have been battered this year by a failed trial of its Vytorin cholesterol drug, reported a smaller-than-expected drop in quarterly earnings on Wednesday thanks to cost controls.
GlaxoSmithKline’s profit fell 5 percent in the first quarter, hit by falling sales of diabetes drug Avandia and generic competition to other products, the world's second biggest drugmaker said.
GlaxoSmithKline said it had agreed to buy biotechnology company Sirtris Pharmaceuticals for $720 million in cash, in hopes its medicines that modulate an aging-related family of enzymes will be effective against a wide range of diseases.
This halftime report is not brought to you by (pick your prescription drug). So, we're pretty much at the midway point of big pharma's earnings season and Goldman Sachs analyst James Kelly is sizing things up so far...
Australia's Sigma Pharmaceuticals and grocery wholesaler Metcash are in talks over a joint bid for assets being sold by Primary Health Care, both companies said on Tuesday.
The iPhone was big. This could be even bigger, Cramer says.
Merck and Eli Lilly reported earnings today, and CNBC asked the pharmaceutical companies’ chief executives and an analyst to discuss the results and the sector as a whole.
I usually cover pharma earnings from my desk at CNBC HQ in Englewood Cliffs, NJ. But because Merck made a rare offer to interview its Chairman and CEO Dick Clark exclusively this morning I'm out at Merck's idyllic HQ campus in central NJ.
Drug maker Novartis reported a better-than-expected rise in first-quarter profit, thanks to strong vaccine sales, while quarterly sales at Nestle also beat expectations.
Eli Lilly Monday posted lower-than-expected quarterly earnings, as disappointing sales of its Byetta diabetes drug overshadowed growing demand for its other medicines, sending shares 3.4 percent lower.
Genentech's blockbuster cancer drug Avastin faces a big challenge from ImClone Systems's Erbitux in lung cancer, Morgan Stanley analysts said on Monday, citing unpublished data.
The irreverent producers of "Squawk on the Street" who are stationed in the pod next to mine here at CNBC like to call it "Pharmapalooza." They're referring to weeks like the one coming up when nearly every big drug company reports earnings.
Roche Holding missed forecasts with a meagre 2 percent increase in first-quarter sales in local currencies, hit by plunging Tamiflu revenue and a slowing pace of growth for cancer drugs.
The world's biggest drug company kicked off pureplay pharma earnings season this morning with disappointing results that look to be dragging down the whole sector. PFE missed Wall Street expectations on revenue and profits.
European shares fell on Thursday, led lower by Nokia after the world's biggest maker of mobile phones failed to impress investors with its outlook, dragging down other technology and telecom stocks.